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Abstract – Tendon pathologies are a group of musculoskeletal conditions frequently seen in clinical practice.
They can be broadly classified into traumatic, degenerative and overuse-related tendinopathies. Rotator cuff tears,
Achilles tendinopathy and tennis elbow are common examples of these conditions. Conventional treatments have
shown inconsistent outcomes and might fail to provide satisfactory clinical improvement. With the growing trend
towards the use of mesenchymal stem cells (MSCs) in other branches of medicine, there is an increasing interest
in treating tendon pathologies using the bone marrow MSC. In this article, we provide a systematic literature review
documenting the current status of the use of bone marrow aspirate concentrate (BMAC) for the treatment of tendon
pathologies. We also asked the question on the safety of BMAC and whether there are potential complications
associated with BMAC therapy. Our hypothesis is that the use of BMAC provides safe clinical benefit when used
for the treatment of tendinopathy or as a biological augmentation of tendon repair. We followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist while preparing this systematic
review. A literature search was carried out including the online databases of PubMed, EMBASE, ClinicalTrial.gov
and the Cochrane Library from 1960 to the end of May 2015. Relevant studies were selected and critically appraised.
Data from eligible studies were extracted and classified per type of tendon pathology. We included 37 articles
discussing the application and use of BMAC for the treatment of tendon pathologies. The Critical Appraisal Skills
Program (CASP) appraisal confirmed a satisfactory standard of 37 studies. Studies were sub-categorised into: tech-
niques of extraction, processing and microscopic examination of BMAC (n = 18), where five studies looked at the
evaluation of aspiration techniques (n = 5), augmentation of rotator cuff tears (n = 5), augmentation of tendo-achilles
tendon (n = 1), treatment of gluteal tendon injuries (n = 1), management of elbow epicondylitis (n = 2), management
of patellar tendinopathy (n = 1) and complications related to BMAC (n = 5). Multiple experimental studies investi-
gated the use of BMAC for tendon repair; nonetheless, there are only limited clinical studies available in this field.
Unfortunately, due to the scarcity of studies, which were mainly case series, the current level of evidence is weak.
We strongly recommend further future randomised controlled studies in this field to allow scientists and clinicians
make evidence-based conclusions.
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Introduction
Tendon pathologies are a group of musculoskeletal condi-
tions frequently seen in clinical practice. Tendons convey
forces from muscles to bone and are repetitively exposed to
mechanical loading. Per se, they are vulnerable to pathological
transformations, known as tendinopathy. Tendinopathy is a
comprehensive term including painful disorders ensuing in
and around tendons. Their common clinical presentation is
with pain and/or weakness and they can have a significant
influence on a patient’s quality of life. Tendinopathy is
particularly predominant in activities that include repetitive*Corresponding author: mohamed.imam@aol.com
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movements, indicative that the increased mechanical loading
acting on tendons is a main contributor to the development
of tendinopathy [1]. Yet, the exact pathogenesis of tendinopa-
thy remains unclear. The characteristic histopathological
characteristics of tendinopathy have been recognised, compris-
ing the accumulation of fat cells, mucoid degeneration, tissue
calcification or combinations of all [2]. These findings suggest
that tendons contain cells with the potential to exhibit multi-
phenotypes that differ from tenocytes, the resident cells in
tendons, which express the fibroblast phenotype [3].
Conventional treatments, such as non-steroidal anti-
inflammatory drugs (NSAIDs), corticosteroid injections,
exercise-based physical therapy, physical therapy modalities,
shock wave therapy, sclerotherapy, nitric oxide patches,
surgery, and growth factors, have shown inconsistent out-
comes. With the growing evidence advocating the use of
mesenchymal stem cells (MSCs) in many branches of medi-
cine, clinicians have shown considerable interest in treating
tendon pathologies using the bone marrow MSC derived from
Bone Marrow Aspirate (BMA). The key characteristic of bone
marrow MSCs is their capability to proliferate and differentiate
into a variety of cell lines and therefore instigate repair [4, 5].
MSC expansion for therapeutic use has recently been classified
as an advanced therapeutic medicinal product, which results in
significant expense and regulation [6]. Bone Marrow Aspirate
Concentrate (BMAC) is generated in a one-step process and
attempts to concentrate the mononucleate cells in order to
potentially harness its reparative potential [7]. In vitro studies
have shown promising results with the use of BMAC as an
augment for Achilles tendon repair [8]. By 28 days after surgi-
cal repair, the failure load for rat Achilles treated with BMAC
becomes equivalent to that of uninjured tendon [9].
In this article, we provide a systematic literature review
documenting the current status of the use of BMAC for the
treatment of tendon pathologies. We also assessed potential
complications associated with the BMAC therapy. Our hypoth-
esis is that the use of BMAC provides clinical benefit when
used for the treatment of tendinopathy or as a biological
augmentation of tendon repair.
Methods
Criteria for selecting studies for this review
We included studies that fulfill the following criteria:
1. studies describing the development and techniques of
BMAC;
2. studies reporting the safety and/or efficacy of BMAC in
tendon pathologies;
3. studies on human subjects with tendon pathologies.
We excluded studies that were not on humans. There were
no restrictions in terms of language and study design.
Search strategy
We performed a computer literature search of online
databases: PubMed, EMBASE, ClinicalTrial.gov and the
Cochrane Library from 1960 to the end of August 2016.
We used the following keywords: (‘‘Bone’’ AND ‘‘Marrow’’
AND ‘‘Aspirate’’ AND ‘‘Concentrate’’).
Study identification
The title and abstract of each study within the results list
were reviewed independently by three authors (MAI, JH, and
SH). Any disagreement was resolved by discussion with the
senior author. Full-text papers of relevant studies were subse-
quently obtained and reviewed against the eligibility criteria.
Then, full texts of the eligible studies were further evaluated
and references were checked for more suitable studies.
The included studies were classified according to the type of
tendon pathology.
Critical appraisal
Two authors using the Critical Appraisal Skills Program
(CASP) checklist [10] independently appraised eligible studies.
For the narrative review, relevant studies were included,
irrespective of the methodology or level of evidence.
Results and discussion
The literature search yielded 89 records. Of these, 37 were
eligible for inclusion and assessment in this review (Figure 1).
The CASP appraisal confirmed a satisfactory standard
of 37 studies. They all had clearly defined objectives, were
well designed and conducted appropriately to meet them.
The published studies reported techniques of collection and
preparation of BMAC in addition to its applications in many
orthopaedic subspecialities. Studies could be sub-categorised
into: techniques of extraction, processing and microscopic
examination of BMAC (n = 18), where five studies looked at
the evaluation of aspiration techniques (n = 5), augmentation
of rotator cuff tears (n = 5), augmentation of Tendo-Achilles
tendon (n = 1), treatment of gluteal tendon injuries (n = 1),
management of elbow epicondylitis (n = 2), management of
patellar tendinopathy (n = 1) and complications related to
BMAC (n = 5).
Bone marrow composition
The cellular composition of the marrow aspirate in normal
individuals has been evaluated by Bain [11]. They assessed
small volumes (0.1–0.2 mL) in 50 subjects. They reported
that neutrophils and erythroblasts formed a major percentage
of the aspirate with differences noticed between the sexes.
Nevertheless, erythroblasts were higher at 28.1% in men com-
pared to 22.5% in women, tending to represent the variations in
adult haemoglobin concentrations. The other components
included lymphocytes 13.1%, eosinophils 2.2%, blast cells
1.4, monocytes 1.3%, and basophils 0.1%. From this analysis
it was notable that there was a broad variation in the megakary-
ocyte percentage. Subsequently, this explains the extensive
variation in normal ranges in the adult population [11].
Additionally, Yamamura et al. [12] gauged the configuration
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of the BMA on the cellular level by laser photometry. Their
observations on the average subpopulation percentages per
0.5 mL of BMA were consistent with the findings of Bain
[11]. They observed that neutrophils constitute the largest cell
population (45.9%) in marrow aspirate, followed by erythrob-
lasts (24.6%), lymphocytes (13.4%), monocytes (8.1%),
eosinophils (2.7%) and basophils (0.1%) [7]. Blast cells made
up 2.1% of the cell populations analysed [7]. Although the
mechanism of cellular analysis differs, the percentage of each
cell type is largely similar. Kim et al. [13] found similar per-
centages using a flow cytometry technique analysing 2 mL
of BMA from haematology patients without active disease.
Bone marrow harvest
Different marrow harvest sources have been described in
the literature. In a study carried out by Hyer et al. [14], they
compared the iliac crest, tibia and calcaneus. These are
regarded as the commonly available areas for harvesting the
BMA. They assessed the number of osteoblastic connective
tissue progenitor cells (OPG) from the aspirates harvested.
They demonstrated that the iliac crest produced a superior
average concentration of OPG compared to the tibia and calca-
neus. Consequently, a larger amount of BMA is required when
aspirating from the tibia or calcaneus to achieve a similar
aspirate of MSCs gained from the iliac crest. Furthermore,
Pierini et al. [15] inspected the harvest achieved from the iliac
crest and demonstrated that the posterior iliac crest produced
1.6-fold more OPG than the anterior crest. Nevertheless, the
posterior iliac crest is more technically challenging during
the surgical procedures than the anterior crest. Variables like
gender, smoking status and diabetes were not predictive of
osteoblastic progenitor cell concentration [14].
Muschler et al. [16] showed that as the quantity of marrow
aspirate rose from 2 to 4 mL, the number of OPG cells shrank
by 50%. These observations were originally reported on the
BMA from the iliac crest. Interestingly, this finding is not
exclusive to the iliac crests, as it was also shown in other
Figure 1. Flow diagram of the search results.
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sources for BMA including the spine. This is likely due to
the proportion of blood in the subsequent samples diluting
the concentration of progenitor cells and colony forming
units/stem cells.
Aiming at achieving safe aspiration of the marrow,
Hernigou et al. [17] have developed the sector rule for BMA
from the iliac crest, which he popularised as the concept of
‘‘safety zones’’. They studied the anatomy of the iliac bone
including the adjacent neurovascular elements that are
susceptible to damage by the trocar when it is introduced into
the iliac crest. The authors used computed tomography (CT) to
examine 48 iliac crests in 24 pelvises. They split the crest into
six even sectors in an anteroposterior course. They studied 480
trocar entry points carried out by six surgeons in 120 subjects.
They established that the sector system reliably envisaged safe
and unsafe zones for placing the trocar in the iliac crest. They
perceived a larger risk of breaches of the cortical bone in obese
patients, and this risk was reduced in the hands of more
experienced surgeons. Ninety-four breaches out of 480 entry
points happened with increased risks observed in the thinner
sectors of the iliac crest. Furthermore, there is added risk of
wounding the external iliac artery in the four most anterior
sectors particularly in females. Instead, posterior sectors were
associated with increased risk of sciatic nerve and gluteal
vessel injury when the trocar was inserted more than 6 cm into
the posterior iliac crest. They established that the sector rule is
a reliable system to use for aspiration of the bone marrow.
Hernigou et al. [18] in another study recognised that
the usage of 10 mL syringes to harvest BMA was superior to
that of 50 mL syringes. In 30 patients the 10 mL syringe aspi-
rations resulted in progenitor cell concentrations on average
300% higher. This was believed to be secondary to a larger
negative pressure generated in the 10 mL syringe, which pref-
erentially removed bone marrow cells and reduced blood
contamination.
Bone marrow concentration
The main concern in using BMA to stimulate tissue repair/
regeneration is the low concentration of MSCs found within it,
as only 0.001% of nucleated cells within BMA are actual
MSCs. The reported concentration of MSCs in bone marrow
is 7–30 cells per million nucleated cells [19]. To address this
issue, various protocols have been developed to concentrate
the nucleated cell numbers to produce BMAC. Therefore,
increasing the amount of MSCs is an attempt to provide an
effective environment for healing and regeneration [5, 7, 19].
Hernigou et al. [20] highlighted that the efficacy of BMAC
is dependent on the amount of progenitor cells in the concen-
trate. They compared the quantity and concentration of these
cells in both BMA and BMAC aspirated from the iliac crest
when used for the treatment of atrophic non-union of the tibia.
The BMA contained a mean of 612 ± 134 compared to
2579 ± 1121 cells per cm3 in the BMAC group. Reduced
concentration of progenitor cells at the non-union sites was
significantly associated (P < 0.01) with non-union [20].
Different techniques have been proposed to concentrate
the bone marrow aspirate to form BMAC. These include the
use of Ficoll density gradients in the laboratory setting and
automated, closed centrifugation systems in the clinical setting
[6]. Although these techniques increase the number of MSCs,
they do not significantly increase the ratio of stem cells to other
nucleated cells [5, 19, 21]. Centrifugation is the present
technique of choice for the various commercially available
products used in the clinical setting, although as shown in rela-
tion to platelet-rich plasma (PRP) there is a significant varia-
tion in the final end products achieved. Fortier et al. [22]
compared the constituents of PRP and BMAC, and observed
that there are reduced platelets and raised white blood cells
(WBCs) in BMAC demonstrating that this is a very different
substance to PRP with a likely different mechanism of action.
The concept of BMAC is to improve the recovery of the
nucleated cells from the marrow aspirate, while decreasing
the recovery of non-nucleated cells such as Red blood cells
(RBCs). The exact mechanism of action of BMAC is currently
not fully understood. Potentially the MSCs contained within
the BMAC provide a direct cell source for repair of the host
tissue. In addition, the nucleated cells may deliver various
cytokines and growth factors into the delivery site to orches-
trate and direct host repair [23–26]. Multiple reports have
described clinical improvement in different conditions includ-
ing stroke, diabetes, and Parkinson’s disease after the systemic
or local use of bone marrow MSC [27, 28]. Until recently it
was widely believed that after administration of bone marrow
MSC, mesenchymal cells differentiate into the target cells and
participate in the repair process. Nonetheless, it is suggested
that healing capabilities of MSC are mainly through chemical
mediators and cytokines which can communicate to the injured
tissue and control cell proliferation, angiogenesis and inflam-
matory process required for repair [29]. Unfortunately, there
are very limited published studies on the uses of BMAC in
the management of tendon pathologies.
MSCs are believed to have multipotent plasticity with the
capability to differentiate along multiple cell lineages such as
cartilage, bone, tendon, muscle and nerve [4, 29–33]. Such
multipotency has the potential to play an important role in the
repair and reconstruction of multiple tissues across a number
of orthopaedic specialties [7]. Various animal and investiga-
tional studies have shown that BMAC can influence tendon
repair; still, there are few clinical studies available [34–36].
McCarrel and Fortier demonstrated potentially optimal release
of growth factors for the management of injuries in tendons and
ligaments [26]. In one equine study, BMAC harvested from the
sternum improved the function of 72% horses with tendon/
ligament pathology and allowed them to return back to race
competition [37]. Similarly, in another case series on racehorses
with tendon and ligament injuries treated with BMAC and PRP,
authors reported significant and marked improvement in all
horses and a return to competition in 84% [38].
Rotator cuff tears
Tendon pathologies can range from tendinopathy to
complete tear, with the rotator cuff, Achilles and the common
extensor origin the most commonly affected. Despite improve-
ments in surgical knowledge and technology, repairs of
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full-thickness cuff tears may be associated with re-tear rates of
25%–57% [39, 40]. Nowadays, a better knowledge about the
healing of rotator cuff tendons and the nature of tears has
guided the pursuit for an answer that tackles not only the
mechanical aspects but also the biological side of healing.
Such a resolution may lead to better healing and subsequent
regeneration of the tendons. In a case series reported by Ellera
Gomes et al. [41], 14 patients (nine women, five men) with
full-thickness rotator cuff tears were managed with trans-
osseous stitches augmented with BMAC utilizing a mini-open
technique. All patients were followed up for a minimum of one
year. Magnetic resonance imaging (MRI) scans were under-
taken to assess tendon integrity at one-year post-surgery. They
reported significant improvement in the University of
California Los Angeles (UCLA) score from 12 ± 3.0 to
31 ± 3.2 at 12 months post-surgery. Tendon integrity was
maintained in all cases while six patients (42%) displayed
the formation of a high-signal intensity at the critical zone.
One revision was reported at two years follow-up. The authors
concluded that BMAC could be safely implanted as an
augment in rotator cuff repairs.
Hernigou et al. [42] evaluated the efficiency of BMAC in
augmenting arthroscopic single row rotator cuff repair in 45
patients. Their primary objective was to compare tendon heal-
ing in the BMAC group to that of a matched control group of
45 patients without augmentation with BMAC. They found
that patients treated with BMAC demonstrated superior out-
comes in terms of tendon healing rate and enhanced quality
of the repaired tendon, as demonstrated by ultrasound and
MRI. Forty-five shoulders (100%) in the BMAC group demon-
strated tendon healing by six months, compared to only 30
shoulders (67%) in the control group at the same time point.
Furthermore, at the latest follow-up of 10 years, the integrity
of the repair was maintained in 39 (87%) shoulders in the
BMAC group compared to only 20 (44%) shoulders in the
control group.
In 2015, Havlas et al. [43] reported the efficiency of aug-
menting cuff repairs with BMAC. BMAC was utilised in com-
bination with single row rotator cuff repair in 45 patients. They
compared the outcomes to those of a control group of 45
patients in which BMAC was not utilised. They reported that
the BMAC injection enhanced the healing rate and improved
the quality of the repaired tendon as determined by the MRI
and Ultrasound (US). Forty-five (100%) compared to 30
(67%) rotator cuff tears had healed by six months as shown
on MRI in the BMAC and control group, respectively. The
BMAC injection also prevented further ruptures during the
next 10 years. This study showed that a significant improve-
ment in healing outcomes could be achieved using BMAC as
an adjunct to rotator cuff repair. The authors reported no
adverse effects of BMAC therapy post-surgery.
Centeno et al. [44] in 2015 reported, in a prospective
multicentre study, the use of BMAC for the treatment of
osteoarthritis (OA) with and without rotator cuff pathology.
A total of 115 shoulders were treated with BMAC injection
principally for glenohumeral OA with or without rotator cuff
tear. The mean disabilities of the arm, shoulder and hand
score (DASH) and Visual Analogue Score (VAS) improved
significantly from 36.1 to 17.1 (P < 0.001) and 4.3 to
2.4 (P < 0.001), respectively. These results were consistent
with a mean subjective improvement of 48.8%. They reported
no significant adverse events. These studies are summarised
in Table 1.
Lower limb tendon injury
Recently, Stein et al. [45] reviewed 27 patients (28 tendons)
with a mean age of 38.3 years with sport-related Achilles
tendon rupture treated with combined open tendon repair and
injection of BMAC. Their outcomes included complications,
restoration of strength, range of motion, re-rupture, calf
circumference, and the Achilles tendon Total Rupture Score
(ATRS). They reported no re-rupture at final follow-up at an
average of 30 months. They showed that 92% of patients
resumed their sporting activity at six months. This cohort of
patients attained a mean ATRS of 91 points at final follow-
up. One soft tissue complication limited to superficial wound
dehiscence was the reported significant complication, with no
deep or superficial infection and no venous thromboembolic
event. This study demonstrated excellent results, including
no re-ruptures and early mobilization was observed in this
cohort of patients. The efficacy of BMAC in the operative
repair of acute Achilles tendon ruptures warrants further study.
Campbell et al. [46] reported the successful use of BMAC
in symptomatic deficiency of the hip capsule and gluteus
minimus tendon in a professional athlete after the removal of
heterotopic ossification. Over 16 weeks, he received in total
three PRP and two BMAC injections. Repeated BMAC
injections improved his pain and strength as well as the integ-
rity of the hip capsule and gluteus minimus tendon on MRI.
The motion analysis results revealed enhancement in kicking
performance while his subjective pain score steadily reduced
over the treatment time period [46].
Epicondylitis
Traditionally, the chief lesion in lateral epicondylitis was
considered to be inflammatory granulation tissue in the
tendinous portion of the common extensor origin. However,
recent studies have failed to demonstrate the presence of the
inflammatory cascade. Given the presence of tendon degener-
ation within this lesion the expression, epicondylosis, or tendi-
nosis has been advocated as a more suitable term than
epicondylitis. Tendon ruptures are dissimilar to bone, in that
tendon healing does not result in complete healing and a return
to the uninjured state. Conversely, a fibrovascular tissue is
produced which yields to a tendon mechanically weaker than
the native tendon [47].
Moon et al. [48] combined surgical intervention with
BMAC to treat medial or lateral epicondylitis in 26 elbows
(24 patients) that had failed non-operative treatment. They con-
cluded that an injection of BMAC after arthroscopic debride-
ment in elbow tendinitis established faster recovery of daily
activities and clear improvement. They reported 100%
improvement in their visual analogue pain scores and Mayo
elbow performance scores (P < 0.001) at the six months time
point. Ultrasound (US) examination of the treated elbow at the
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final postoperative follow-up revealed healthy uniform orienta-
tion of the tendon. In the cytokine analysis, significantly high
levels of Interleukin-12 (IL-12), Interferon gamma-induced
Protein 10 (IP-10), and Regulated on Activation, Normal T
Cell Expressed and Secreted (RANTES) were detected.
Similar results were reported by Singh et al. [49], a total of
30 patients of formerly untreated lateral epicondylitis were
administered a local injection of BMAC. They assessed the
clinical outcome at baseline, two weeks, six weeks and 12
weeks using the Patient-Rated Tennis Elbow Evaluation
(PRTEE) score. The baseline pre-injection mean PRTEE score
was 72.8 ± 6.97, which decreased to a mean of 40.93 ± 5.94 at
two weeks after injection, which was highly significant
(P < 0.0001). In their final follow-up at 12 weeks, there was
a significant improvement in the mean PRTEE score compared
to the baseline score (72.8 ± 6.9 down to 14.86 ± 3.48). The
authors concluded that an injection of growth factors and stem
cells in the buffy coat layer of BMAC was an effective way of
managing chronic lateral epicondylitis.
Patella tendon tendinopathy
Pascual-Garrido et al. [50] reported the clinical results of a
case series of ultrasound-guided injection of BMAC for
refractory patella tendinitis unresponsive to non-operative
treatment. Their report included eight patients (four males
and four females) aged between 14 and 35 years. The study
reported a significant improvement in pain and activity of daily
living scores, knee-related quality of life and functional knee
scores (International Knee Documentation Committee (IKDC)
and Knee Injury and Osteoarthritis Outcome Score (KOOS)),
in seven out of eight patients treated with ultrasound-guided
injection of BMAC. Seven out of eight patients stated they
would have the procedure again and categorised the outcome
of their treatment as excellent. In this study, the number of
nucleated cells in the BMA was 37 · 103 and after concentra-
tion it reached to 45 · 103.
Potential risks
Marrow aspiration is thought to be a relatively safe
procedure. As with all invasive procedures, patients should
have consented with regard to all possible risks [51–54]. These
risks can be associated with harvesting the BMA or with the
application of BMAC.
Risks of harvest
In order to investigate the risks of BMA harvest, Bain [51]
undertook a multicentre study surveying 19,259 procedures.
Haemorrhage occurred in 11 (0.0005%) patients. Associated
anticoagulation therapy was the most significant risk factor
for haemorrhage. Superficial infection has been reported in
two subjects, and both of them were successfully treated with
antibiotics. While pain is dependent on the site of harvest,
chronic pain can be a potential concern. The pain might not
spontaneously resolve and could be managed by neuropathic
pain medications [52, 54]. Neurovascular injury is another
Table 1. Summary of studies assessing the efficiency of BMAC in the management of rotator cuff tears.
Study ID Design Population Intervention Comparator Outcome measure Findings
Ellera Gomes
et al. [41]
Single arm
prospective
study
Fourteen patients
(nine women, five
men) with full
thickness rotator
cuff tears
Trans-osseous
stitches
augmented with
BMAC utilizing
a mini-open
technique
No control University of
California Los
Angeles
Tendon integrity
(12 months)
From 12 ± 3.0 to
31 ± 3.2
Tendon integrity
was maintained
in 100% of cases.
Hernigou
et al. [20]
Prospective,
matched-control,
study
Fifty-four patients BMAC in
augmenting
arthroscopic
single row
rotator cuff
repair
Matched control
group of 45
patients without
augmentation
with BMAC
Tendon integrity
(six months)
Tendon integrity
(10 years)
100% vs. 67%
87% vs. 44%
Centeno
et al. [44]
Prospective
multicentre
cohort study
Patients with
osteoarthritis with
and without rotator
cuff pathology
BMAC injection
for the gleno-
humeral OA
None – The arm,
shoulder and
hand score
– Visual analogue
score
– Mean subjective
improvement
– Improved from
36.1 to 17.1
(P < 0.001)
– Improved from 4.3
to 2.4 (P < 0.001)
– 48.8%
Havlas
et al. [43]
Prospective,
matched-control,
study
Forty-five patients BMAC in
augmenting
arthroscopic
single row
rotator cuff
repair
Matched control
group of 45
patients without
augmentation
with BMAC
Tendon integrity
(6 months)
(100%) compared to
30 (67%)
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possible risk; the shared worry is the risk of injury to the
neurovascular structures close to the harvest site. Injury to
these structures may result in haemorrhage or problems with
chronic pain. Moreover, pathological fractures are potential
concern especially when there is an underlying metabolic
problem like osteomalacia or bone density pathology like
osteoporosis [51–54]. Lastly, death is an extreme adverse event
that has been reported in one patient in 2001, due to the forma-
tion of a retroperitoneal haematoma after an aspirate from the
posterior iliac crest [51].
Risks of administration
The relevant administration risks are dependent on what
procedure is being carried out, but generally include the risks
given below.
Infection
Infection is still a possibility at the administration site,
although prophylactic antibiotics for the original procedure
itself are common practice in many centers. This risk will be
dependent on the procedure but routine universal aseptic pre-
cautions should be used in order to minimize the risk [51].
Fat embolism and respiratory complications
When used intraosseously, due to bone being permeable to
liquefied material, fat embolisation is a potential risk [55].
Animal studies have shown fat particles in the lungs of dogs
at post-mortem, nevertheless in human trials, adverse clinical
outcomes in the form of respiratory complications or decreased
oxygen saturation have not been reported [56]. Those subjects at
a greater risk of embolization such as those with cardiac shunts
should be considered as to their suitability to receive intraoss-
eous BMAC. In all cases of intraosseous administration,
patients should be monitored for the clinical signs of fat embo-
lism [24]. In the clinical experience of Hernigou et al., no respi-
ratory complications or changes in oxygen saturation have been
seen [19]. Hitherto, considering Orlowski et al.’s findings, a
BMAC intraosseous injection should be used with caution and
should not be used in subjects with a right to left intracardiac
shunt due to the risk of embolism to the vital organs.
Finally, there are limitations in this study. As for all system-
atic reviews, this is a pooled analysis of case series and
retrospective studies of Level IV of evidence. Hence, there is
the risk of bias and other confounding variables. Nevertheless,
to the best of our knowledge, this is the first review examining
the uses of BMAC in the management of tendon pathology.
Moreover, there are so few studies to review that assess
multiple different tendinopathies, which may respond differ-
ently to this treatment.
Risk of tumorigenesis
One of the greatest concerns with delivering BMAC into a
new site is the possibility for tumorigenesis. Nevertheless, this
theory is unproven in one big series by Hernigou et al. [57].
Between 1990 and 2006, they retrospectively reviewed 1873
patients managed with BMAC at a mean follow-up of
12.5 years. Patients were examined for the occurrence of
cancer from the date of the first operation until death.
They reviewed more than 7300 MRIs and 52,000 radiographs.
They reported the diagnosis of malignancy in 53 cases.
All 53 cancers were diagnosed in areas other than the BMAC
injection site. Nonetheless, as per the reported incidence of
cancer in the general population, the anticipated incidence over
the same study period was theoretically between 97 and 108.
This study found no increased cancer risk in patients after the
application of BMAC either at the administration site or
elsewhere in 1873 patients after an average follow-up period
of 12.5 years.
Conclusions
In conclusion, MSCs in BMAC are able to self-renew and
possibly differentiate into different tissues. Furthermore, MSCs
are known to control the immune system and have a conceiv-
able positive paracrine influence. BMAC has been mostly used
to encourage bone formation and treat avascular necrosis
(AVN) of the femoral head, with encouraging results. There
is increasing interest in the use of BMAC in tendon pathologies
with early results displaying promise. Alongside well-designed
randomised controlled clinical trials, further basic science
work is required to investigate the therapeutic action of
BMAC. The commercial processing of BMAC should be
enhanced to accomplish a reliable end product, which will
deliver predictable results.
We have investigated the clinical use of BMAC in tendon
pathologies using all available published studies. Unfortunately,
there is still limited evidence available given the small number
of published studies. The reviewed articles did not report any
significant complications directly related to the use of BMAC
in tendon pathologies; however apart from one study with a
10-year follow-up [42], all other clinical studies had short- to
medium-term follow-up. We believe there is sufficient promis-
ing data to warrant further well-designed clinical studies to
allow scientists and clinicians to make evidence-based deci-
sions regarding the use of BMAC in tendon injuries.
Conflict of interest
The authors declare that they have no conflict of interest in
relation with this paper.
References
1. Zhang J, Wang JH (2010) Mechanobiological response of
tendon stem cells: implications of tendon homeostasis and
pathogenesis of tendinopathy. J Orthop Res 28(5), 639–643.
2. Kannus P, Jozsa L (1991) Histopathological changes preceding
spontaneous rupture of a tendon. A controlled study of 891
patients. J Bone Joint Surg Am 73(10), 1507–1525.
3. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC,
Sonoyama W, Li L, Leet AI, Seo BM, Zhang L, Shi S, Young
MF (2007) Identification of tendon stem/progenitor cells and
M.A. Imam et al.: SICOT J 2017, 3, 58 7
the role of the extracellular matrix in their niche. Nat Med
13(10), 1219–1227.
4. Bruder SP, Jaiswal N, Haynesworth SE (1997) Growth
kinetics, self-renewal, and the osteogenic potential of purified
human mesenchymal stem cells during extensive subcultivation
and following cryopreservation. J Cellular Biochem 64(2),
278–294.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R,
Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR
(1999) Multilineage potential of adult human mesenchymal
stem cells. Science 284(5411), 143–147.
6. Holton J, Imam M, Ward J, Snow M (2016) The basic science
of bone marrow aspirate concentrate in chondral injuries.
Orthop Rev (Pavia) 8(3), 6659.
7. Imam MA, Mahmoud SSS, Holton J, Abouelmaati D,
Elsherbini Y, Snow M (2017) A systematic review of the
concept and clinical applications of bone marrow aspirate
concentrate in orthopaedics. SICOT-J 3, 17.
8. Broese M, Toma I, Haasper C, Simon A, Petri M, Budde S,
Wehmeier M, Krettek C, Jagodzinski M (2011) Seeding a
human tendon matrix with bone marrow aspirates compared to
previously isolated hBMSCs – an in vitro study. Technol Health
Care 19(6), 469–479.
9. Okamoto N, Kushida T, Oe K, Umeda M, Ikehara S, Iida H
(2010) Treating Achilles tendon rupture in rats with bone-
marrow-cell transplantation therapy. J Bone Joint Surg Am
92(17), 2776–2784.
10. Nadelson S, Nadelson LS (2014) Evidence-based practice
article reviews using CASP tools: a method for teaching EBP.
Worldviews Evid Based Nurs 11(5), 344–346.
11. Bain BJ (1996) The bone marrow aspirate of healthy subjects.
Br J Haematol 94(1), 206–209.
12. Yamamura R, Yamane T, Hino M, Ohta K, Shibata H, Tsuda I,
Tatsumi N (2002) Possible automatic cell classification of bone
marrow aspirate using the CELL-DYN 4000 automatic blood
cell analyzer. J Clin Lab Anal 16(2), 86–90.
13. Kim M, Kim J, Lim J, Kim Y, Han K, Kang CS (2004) Use of
an automated hematology analyzer and flow cytometry to
assess bone marrow cellularity and differential cell count. Ann
Clin Lab Sci 34(3), 307–313.
14. Hyer CF, Berlet GC, Bussewitz BW, Hankins T, Ziegler HL,
Philbin TM (2013) Quantitative assessment of the yield of
osteoblastic connective tissue progenitors in bone marrow
aspirate from the iliac crest, tibia, and calcaneus. J Bone Joint
Surg Am 95(14), 1312–1316.
15. Pierini M, Di Bella C, Dozza B, Frisoni T, Martella E,
Bellotti C, Remondini D, Lucarelli E, Giannini S, Donati D
(2013) The posterior iliac crest outperforms the anterior iliac
crest when obtaining mesenchymal stem cells from bone
marrow. J Bone Joint Surg Am 95(12), 1101–1107.
16. Muschler GF, Boehm C, Easley K (1997) Aspiration to obtain
osteoblast progenitor cells from human bone marrow: the
influence of aspiration volume. J Bone Joint Surg Am 79(11),
1699–1709.
17. Hernigou J, Picard L, Alves A, Silvera J, Homma Y, Hernigou P
(2014) Understanding bone safety zones during bone marrow
aspiration from the iliac crest: the sector rule. Int Orthop
38(11), 2377–2384.
18. Hernigou P, Homma Y, Flouzat Lachaniette CH, Poignard A,
Allain J, Chevallier N, Rouard H (2013) Benefits of small
volume and small syringe for bone marrow aspirations of
mesenchymal stem cells. Int Orthop 37(11), 2279–2287.
19. Hernigou P, Poignard A, Beaujean F, Rouard H (2005)
Percutaneous autologous bone-marrow grafting for nonunions
Influence of the number and concentration of progenitor cells.
J Bone Joint Surg Am 87(7), 1430–1437.
20. Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F,
Rouard H (2006) Percutaneous autologous bone-marrow
grafting for nonunions. Surgical technique. J Bone Joint Surg
Am 88(Suppl 1 Pt 2), 322–327.
21. Kasten P, Beyen I, Egermann M, Suda AJ, Moghaddam AA,
Zimmermann G, Luginbuhl R (2008) Instant stem cell therapy:
characterization and concentration of human mesenchymal
stem cells in vitro. Euro Cell Mater 16, 47–55.
22. Fortier LA, Potter HG, Rickey EJ, Schnabel LV, Foo LF,
Chong LR, Stokol T, Cheetham J, Nixon AJ (2010) Concen-
trated bone marrow aspirate improves full-thickness cartilage
repair compared with microfracture in the equine model.
J Bone Joint Surg Am 92(10), 1927–1937.
23. Lee DH, Ryu KJ, Kim JW, Kang KC, Choi YR (2014) Bone
marrow aspirate concentrate and platelet-rich plasma enhanced
bone healing in distraction osteogenesis of the tibia. Clin
Orthop Relat Res 472(12), 3789–3797.
24. Jager M, Jelinek EM, Wess KM, Scharfstadt A, Jacobson M,
Kevy SV, Krauspe R (2009) Bone marrow concentrate: a novel
strategy for bone defect treatment. Curr Stem Cell Res Therapy
4(1), 34–43.
25. Muschler GF, Nitto H, Matsukura Y, Boehm C, Valdevit A,
Kambic H, Davros W, Powell K, Easley K (2003) Spine fusion
using cell matrix composites enriched in bone marrow-derived
cells. Clin Orthop Relat Res 407, 102–118.
26. McCarrel T, Fortier L (2009) Temporal growth factor
release from platelet-rich plasma, trehalose lyophilized
platelets, and bone marrow aspirate and their effect on
tendon and ligament gene expression. J Orthop Res 27(8),
1033–1042.
27. Chopp M, Li Y, Zhang ZG (2009) Mechanisms underlying
improved recovery of neurological function after stroke in the
rodent after treatment with neurorestorative cell-based thera-
pies. Stroke 40(3 Suppl), S143–S145.
28. Schwarz SC, Schwarz J (2010) Translation of stem cell therapy
for neurological diseases. Transl Res 156(3), 155–160.
29. Baksh D, Song L, Tuan RS (2004) Adult mesenchymal stem
cells: characterization, differentiation, and application in cell
and gene therapy. J Cell Mol Med 8(3), 301–316.
30. Gulotta LV, Kovacevic D, Ehteshami JR, Dagher E, Packer JD,
Rodeo SA (2009) Application of bone marrow-derived mes-
enchymal stem cells in a rotator cuff repair model. Am J Sports
Med 37(11), 2126–2133.
31. Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH
(2010) Autologous bone marrow-derived mesenchymal
stem cells versus autologous chondrocyte implantation: an
observational cohort study. Am J Sports Med 38(6),
1110–1116.
32. Brazelton TR, Rossi FM, Keshet GI, Blau HM (2000) From
marrow to brain: expression of neuronal phenotypes in adult
mice. Science 290(5497), 1775–1779.
33. Kopen GC, Prockop DJ, Phinney DG (1999) Marrow
stromal cells migrate throughout forebrain and cerebellum,
and they differentiate into astrocytes after injection into
8 M.A. Imam et al.: SICOT J 2017, 3, 58
neonatal mouse brains. Proc Natl Acad Sci USA 96(19),
10711–10716.
34. Hayashi M, Zhao C, An KN, Amadio PC. (2011). The effects of
growth and differentiation factor 5 on bone marrow stromal cell
transplants in an in vitro tendon healing model. J Hand Surg
Eur Vol 36(4), 271–279.
35. Morizaki Y, Zhao C, An KN, Amadio PC (2010) The effects of
platelet-rich plasma on bone marrow stromal cell transplants for
tendon healing in vitro. J Hand Surg 35(11), 1833–1841.
36. Zhao C, Chieh HF, Bakri K, Ikeda J, Sun YL, Moran SL,
An KN, Amadio PC (2009) The effects of bone marrow stromal
cell transplants on tendon healing in vitro. Med Eng Phys
31(10), 1271–1275.
37. Renzi S, Ricco S, Dotti S, Sesso L, Grolli S, Cornali M,
Carlin S, Patruno M, Cinotti S, Ferrari M (2013) Autologous
bone marrow mesenchymal stromal cells for regeneration of
injured equine ligaments and tendons: a clinical report. Res Vet
Sci 95(1), 272–277.
38. Torricelli P, Fini M, Filardo G, Tschon M, Pischedda M,
Pacorini A, Kon E, Giardino R (2011) Regenerative medicine
for the treatment of musculoskeletal overuse injuries in
competition horses. Int Orthop 35(10), 1569–1576.
39. Neyton L, Godeneche A, Nove-Josserand L, Carrillon Y,
Clechet J, Hardy MB (2013) Arthroscopic suture-bridge repair
for small to medium size supraspinatus tear: healing rate and
retear pattern. Arthroscopy 29(1), 10–17.
40. Imam MA, Abdelkafy A (2016) Outcomes following
arthroscopic transosseous equivalent suture bridge double row
rotator cuff repair: a prospective study and short-term results.
SICOT-J 2, 7.
41. Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR,
Pellanda R (2012) Conventional rotator cuff repair comple-
mented by the aid of mononuclear autologous stem cells. Knee
Surg Sports Traumatol Arthrosc 20(2), 373–377.
42. Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S,
Duffiet P, Chevallier N, Rouard H (2014) Biologic augmenta-
tion of rotator cuff repair with mesenchymal stem cells during
arthroscopy improves healing and prevents further tears: a case-
controlled study. Int Orthop 38(9), 1811–1818.
43. Havlas V, Kotaska J, Konicek P, Trc T, Konradova S, Koci Z,
Sykova E (2015) Use of cultured human autologous bone
marrow stem cells in repair of a rotator cuff tear: preliminary
results of a safety study. Acta Chir Orthop Traumatol Cech
82(3), 229–234.
44. Centeno CJ, Al-Sayegh H, Bashir J, Goodyear S, Freeman MD
(2015) A prospective multi-site registry study of a specific
protocol of autologous bone marrow concentrate for the
treatment of shoulder rotator cuff tears and osteoarthritis.
J Pain Res 8, 269–276.
45. Stein BE, Stroh DA, Schon LC (2015) Outcomes of acute
Achilles tendon rupture repair with bone marrow aspirate
concentrate augmentation. Int Orthop 39(5), 901–905.
46. Campbell KJ, Boykin RE, Wijdicks CA, Erik Giphart J,
LaPrade RF, Philippon MJ (2013) Treatment of a hip capsular
injury in a professional soccer player with platelet-rich plasma
and bone marrow aspirate concentrate therapy. Knee Surg
Sports Traumatol Arthrosc 21(7), 1684–1688.
47. Gott M, Ast M, Lane LB, Schwartz JA, Catanzano A,
Razzano P, Grande DA (2011) Tendon phenotype should
dictate tissue engineering modality in tendon repair: a review.
Discov Med 12(62), 75–84.
48. Moon YL, Jo SH, Song CH, Park G, Lee HJ, Jang SJ (2008)
Autologous bone marrow plasma injection after arthroscopic
debridement for elbow tendinosis. Ann Acad Med Singapore
37(7), 559–563.
49. Singh A, Gangwar DS, Singh S (2014) Bone marrow injection:
a novel treatment for tennis elbow. J Nat Sci Biol Med 5(2),
389–391.
50. Pascual-Garrido C, Rolon A, Makino A (2012) Treatment
of chronic patellar tendinopathy with autologous bone
marrow stem cells: a 5-year-followup. Stem Cells Int 2012,
953510.
51. Bain BJ (2005) Bone marrow biopsy morbidity: review of
2003. J Clin Pathol 58(4), 406–408.
52. Burkle CM, Harrison BA, Koenig LF, Decker PA,
Warner DO, Gastineau DA (2004) Morbidity and mortality of
deep sedation in outpatient bone marrow biopsy. Am J Hematol
77(3), 250–256.
53. Bain BJ (2004) Bone marrow biopsy morbidity and mortality:
2002 data. Clin Lab Haematol 26(5), 315–318.
54. Bain BJ. 2003. Bone marrow biopsy morbidity and mortality.
Br J Haematol 121(6), 949–951.
55. Husebye EE, Lyberg T, Roise O (2006) Bone marrow fat in
the circulation: clinical entities and pathophysiological
mechanisms. Injury 37(Suppl 4), S8–S18.
56. Orlowski JP, Julius CJ, Petras RE, Porembka DT, Gallagher JM
(1989) The safety of intraosseous infusions: risks of fat and
bone marrow emboli to the lungs. Ann Emerg Med 18(10),
1062–1067.
57. Hernigou P, Homma Y, Flouzat-Lachaniette CH, Poignard A,
Chevallier N, Rouard H (2013) Cancer risk is not increased
in patients treated for orthopaedic diseases with autologous
bone marrow cell concentrate. J Bone Joint Surg Am 95(24),
2215–2221.
Cite this article as: Imam MA, Holton J, Horriat S, Negida AS, Grubhofer F, Gupta R, Narvani A & Snow M (2017) A systematic review of
the concept and clinical applications of bone marrow aspirate concentrate in tendon pathology. SICOT J, 3, 58
M.A. Imam et al.: SICOT J 2017, 3, 58 9
